OncoMatch/Clinical Trials/SSGJ-707
SSGJ-707 (PF-4404) Clinical Trials
SSGJ-707 (PF-4404) is a recombinant humanized IgG4 bispecific antibody targeting both PD-1 and VEGF, designed to combine checkpoint blockade with tumor vascular disruption in a single agent. Phase 2 monotherapy data in first-line PD-L1–positive NSCLC demonstrated promising efficacy, prompting a Phase 3 global development program with US sites led by Pfizer, which completed an exclusive ex-China licensing agreement with 3SBio in 2025. Trials also evaluate SSGJ-707 in combination with chemotherapy in colorectal cancer and in gynecologic malignancies. Eligibility typically specifies PD-L1 expression thresholds and, for combination arms, prior therapy status.
Check your eligibilityRecruiting SSGJ-707 trials
Ranked by phase and US site count. Filter by your biomarker profile →
SSGJ-707 is under active investigation across multiple tumor types.
How OncoMatch helps you find SSGJ-707 trials
AI reads the protocol
OncoMatch reads the eligibility criteria for every SSGJ-707 trial and extracts structured requirements — biomarkers, stage, prior therapy — from protocol text.
Enter your results
Select your cancer type and mark your biomarker results. Your data never leaves your device. OncoMatch instantly filters to trials you may qualify for.
See your matches
Each trial shows which criteria you meet, which you don't, and which need more information. Bring the shortlist to your oncologist.